|
n (%)
|
86 (53.75%)
|
74 (46.25%)
| |
|
Age at diagnosis, median (range), years
|
71.5 (43–100)
|
69.5 (28–90)
|
0.470c
|
|
Gender (M/F)
|
52/34
|
40/34
|
0.427
|
|
Tumor Stage (locally advanced/metastatic)
|
16/70
|
18/56
|
0.440
|
|
Tumor location (head/body/tail)
|
46/33/7
|
47/21/6
|
0.396
|
|
Tumor size, mean ± SD (cm)
|
4.5 ± 1.5
|
4.1 ± 1.5
|
0.828d
|
|
Patients with CA 19–9 > 1000 U/mL at diagnosisa
|
40 (55.5%)
|
33 (47.8%)
|
0.401
|
|
Weight loss > 10% BW at diagnosis, n (%)
|
47 (54.7%)
|
48 (64.9%)
|
0.220
|
|
Patients receiving palliative chemotherapy, n (%)
|
40 (46.5%)
|
53 (71.6%)
|
0.001
|
|
Number of chemotherapy cycles, median (range)b
|
3 (0.3–20)
|
4 (1–40)
|
0.004c
|
|
Survival, median (range), days
|
95.0 (33–768)
|
189 (31–997)
|
< 0.001c
|
|
Patients receiving PERT, n (%)
|
0 (0%)
|
49 (66.2%)
|
< 0.001
|
